Abstract: Provided herein are desmopressin oral liquid formulations. Also provided herein are methods of making and using desmopressin oral liquid compositions for the treatment of certain diseases including diabetes insipidus, enuresis, hemophilia A, von willebrand disease, high blood urea levels and others.

Abstract: The present disclosure provides extended release atomoxetine compositions suitable for once-daily administration. The compositions comprise a core comprising atomoxetine or a pharmaceutically acceptable salt thereof; and a functional coat/extended release coat over the core. The extended release compositions of the disclosure provide a lag time of at least about 30 minutes during which compositions release less than or equal to 20% of atomoxetine or the pharmaceutically acceptable salt thereof, based on the total weight of atomoxetine or a pharmaceutically acceptable salt thereof present in the composition, measured in 900 mL of a dissolution medium comprising 0.05 M pH 6.8 buffer, using USP Apparatus II (paddle) at 50 rpm and 37° C.

Abstract: Compositions are provided for the liquid oral administration of topiramate and its salts. The invention further provides methods for treating diseases and disorders using the compositions.

Abstract: Compositions are provided for the liquid oral administration of topiramate and its salts. The invention further provides methods for treating diseases and disorders using the compositions.

Abstract: Compositions are provided for the liquid oral administration of topiramate and its salts. The invention further provides methods for treating diseases and disorders using the compositions.

Abstract: Compositions are provided for the liquid oral administration of topiramate and its salts. The invention further provides methods for treating diseases and disorders using the compositions.